Exelixis

Exelixis

Exelixis
Company type	Public company
Traded as	Nasdaq: EXEL
Industry	Biotechnology
Founded	1994
Headquarters	South San Francisco, California, USA
Key people	Michael Morrissey, President, Research and Development Frank Karbe, CFO Gisela M. Schwab, Executive Vice President and Chief Medical Officer Pamela A. Simonton, Executive Vice President and General Counsel Peter Lamb, Senior Vice President, Discovery Research and Chief Scientific Officer Lupe M. Rivera, Senior Vice President, Operations
Website	www.exelixis.com

Exelixis is a genomics-based drug discovery company located in South San Francisco, Ca., and the producer of Cometriq, a treatment for medullary thyroid cancer. It works on the development of anti-cancer therapies. Exelixis has several compounds in various stages of FDA approval including :

• XL147 that targets phosphoinositide-3 kinase (PI3K); and
• XL765, which targets PI3K and mTOR, kinases in the PI3K signaling pathway.
• XL880 (foretinib)

The company also has various compounds in phase 1 clinical trials, including

• XL518, a small molecule inhibitor of the MEK;
• XL228, which targets insulin-like growth factor type 1 receptor, an RTK in a range of human tumors;
• XL139 that targets Hedgehog; XL413, a small molecule inhibitor of the serine-threonine kinase CDC7;
• XL888, a synthetic inhibitor of HSP90, a chaperone protein that promotes the activity and stability of a range of regulatory proteins, including kinases.

Its lead compound, XL184, has been approved for treatment of medullary thyroid cancer and is currently in a number of clinical trials for prostate, ovarian, brain, melanoma, breast, non-small cell lung, hepatocellular, kidney. During its trial for the treatment of medullary thyroid cancer, XL184 was designated orphan drug status by the FDA and given the generic name, cabozantinib. Cabozantinib is an inhibitor of the tyrosine kinases Met and VEGFR2, and has been shown to abrogate tumor growth, metastasis, and angiogenesis.

External links

• Official website